$10 billion for vax research

The Bill and Melinda Gates Foundation said today (January 29) that they will donate $10 billion over the next 10 years to develop vaccines and deliver them to the world's poorest countries. The donation, announced at the World Economic Forum in Switzerland, is the foundation's largest contribution to vaccine research and distribution, more than doubling the $4.5 billion sum it has given over the last five years. Image: Wikimedia commonsWith the money, Microsoft co-founder Bill Gates hopes to ra

Written byJef Akst

| 2 min read

Save for Later

Image: Wikimedia commons

With the money, Microsoft co-founder Bill Gates hopes to raise immunization rates for diarrhea and pneumonia to 90%, which could save some 7.6 million children under the age of five by 2019, according to a model developed at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland, linkurl:Nature News reported.;http://www.nature.com/news/2010/100129/full/news.2010.44.html Furthermore, if the malaria vaccine being developed by GSK -- linkurl:currently in its final testing phase;http://www.the-scientist.com/blog/display/56128/ -- is introduced by 2014, it could save an additional 1.1 million lives, linkurl:the Gates Foundation estimates.;http://www.npr.org/templates/story/story.php?storyId=123101119 "We must make this the decade of vaccines," Gates said in a statement. "Vaccines already save and improve millions of lives in developing countries. Innovation will make it possible to save more children than ever before." (Check out linkurl:our recent feature;http://www.the-scientist.com/2010/1/1/32/1/ on the vaccine development industry, which thanks in part to recent investment in the developing world, is now thriving.) Last year, the Gates Foundation and a number of governments and NGOs donated $1.5 billion towards a vaccine for pneumococcal diseases, such as meningitis and pneumonia, in an advance market commitment -- an approach to encourage a high-volume, low-cost supply of the vaccine to meet the needs of poor countries. Basically, it's a promise to help buy a vaccine that meets certain criteria, linkurl:The Wall Street Journal reported.;http://blogs.wsj.com/health/2010/01/29/bill-gates-vaccines-and-a-15-billion-carrot/ For manufacturers to profit from the vaccine, they must commit to sell it for just $7 per dose -- 10 times less than the going price for the vaccine in the developed world. "We expect that manufacturers will commit to building factories much earlier than they would otherwise in order to compete for this money," Gates wrote in his linkurl:annual letter,;http://www.gatesfoundation.org/annual-letter/2010/Pages/vaccine-innovation-delivery.aspx published earlier this week. "During 2010 the negotiations with manufacturers should come to a conclusion. We believe this will make a big difference in how quickly this vaccine gets to poor children and show how this approach can be applied to other medicines."
**__Related stories:__***linkurl:Nice Shot;http://www.the-scientist.com/2010/1/1/32/1/
[January 2010]*linkurl:A cancer vaccine -- that works?;http://www.the-scientist.com/blog/display/56188/
[25th November 2009]*linkurl:Malaria vaccine hits Phase III;http://www.the-scientist.com/blog/display/56128/
[3rd November 2009]

Meet the Author

Jef Akst

Jef (an unusual nickname for Jennifer) got her master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses. After four years of diving off the Gulf Coast of Tampa and performing behavioral experiments at the Tennessee Aquarium in Chattanooga, she left research to pursue a career in science writing. As The Scientist's managing editor, Jef edited features and oversaw the production of the TS Digest and quarterly print magazine. In 2022, her feature on uterus transplantation earned first place in the trade category of the Awards for Excellence in Health Care Journalism. She is a member of the National Association of Science Writers.

View Full Profile

$10 billion for vax research

The Scientist ARCHIVES

Become a Member of

Meet the Author

Jef Akst

Related Research Resources

What Is the Amniotic Fluid Composed of?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Advancing Drug Discovery with Complex Human In Vitro Models

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Maximizing Cancer Research Model Systems

Products

Product News

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform